Janux Therapeutics, Inc. (JANX) Profit Margins
Over the twelve months to 2026-06-30, Janux Therapeutics, Inc. (JANX) had operating margin -598.1%, net margin -427.5%, free cash flow margin -174.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
JANXJanux Therapeutics, Inc.Follow JANX — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% | -598.1% | |
| Net margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% | -427.5% | |
| FCF margin | -507.5% | -573.2% | -648.6% | -417.2% | -832.8% | -174.7% |
USD billions · SEC XBRL
Janux Therapeutics, Inc. — questions
- What is Janux Therapeutics, Inc.'s operating margin?
- -598.1% over the twelve months to 2026-06-30.
- What is Janux Therapeutics, Inc.'s net profit margin?
- -427.5% over the twelve months to 2026-06-30.
Every figure on this page comes from Janux Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.